Hershberg joins Frazier as venture partner; plus Moses to chair LabGenius, and ViralClear, MorphoSys, Emergent and more

Robert Hershberg has joined Frazier Healthcare Partners as venture partner. The former EVP, CSO and head of BD and global alliances of Celgene Corp. helped coordinate the company’s $74 billion takeout by Bristol Myers Squibb Co. (NYSE:BMY) last year. Hershberg is the second architect behind the acquisition to move on to a VC. Paul Biondi, who was head of strategy and BD at BMS, joined Flagship Pioneering in December (see “Architects Behind Celgene Takeout Step Down”).

LabGenius Ltd., which is using AI to develop proteins, appointed Edwin Moses as chairman. Moses was CEO of Ablynx N.V. in 2006-18 until its $4.8 billion takeout by Sanofi (Euronext:SAN; NASDAQ:SNY) in 2018...